FIGURE S1; Relates to FIGURE1. Targeting of eGFP into the human PDX1 locus. A) The gene encoding green fluorescent protein (GFP) was inserted into the 5' untranslated region of the PDX1 gene in the HUES4 cell line. BD primers amplify the WT allele, AC primers amplify all transgenic clones, and AD primers amplify the targeted allele. HA: homology arm B) Representative PCR screen of 4 targeting events is shown for 4 individual clones (AD primers were used). G = genomic DNA (non-targeted), MQ = MQ H 2 O (negative control), B = BAC, G+B = genomic DNA + BAC. C) Table showing the relative targeting efficiency that was obtained in 3 different hESC lines. D) Copy number determination of integrated targeting vector in PDXeG cells. Quantities of pPDX1 relative to two reference genes were determined for wildtype hESC line (HUES4) and two PDXeG clones (clones 145-3 and 170-3) cultured on MEFs or feeder free (FF). The plots show mean expression ± SEM of technical repeats (n=4; 1 passage was analyzed per cell line except for 170-3 on DEF, where 2 passages were analyzed). E) Fluorescence and corresponding brightfield images are shown of the targeted PDXeG line (clone 170-3) at day 13. Scale bar, 100 µm F) Immunofluorescence images of the PDXeG cell line (clone 170-3) showing co-localization of the endogenous PDX1 expression (red) with GFP (green) at day 16. Scale bar, 50 µm. G) Immunofluorescence analysis of the PDX1(GFP + ) cell population at day 17. A significant number of the GFP + /PDX1 + cells co-expressed NKX6-1, and SOX9. Scale bars, 50 µm.
FIGURE S3; relates to FIGURE 4. Comparison of the cell surface markers CD142 and CD200 with GP2 for purification of pancreatic endoderm cells. A)
Flow cytometry analysis of the previously identified cell surface markers CD142 and CD200 in the PDXeG reporter cell line cultured on MEFs. B) The PDXeG cell line and the genetically untagged HUES4 cell line (C) was differentiated in a feeder free culture system using a previously published protocol (Rezania et al., 2013) and stained with GP2, ITGA4, CD142, and CD200 as indicated. The plots showing CD142 and CD200 are single stainings acquired similarly as plot 1 that depicts a double staining with GP2 and ITGA4. D) qPCR analysis on sorted populations (GP2 -, GP2 + , CD142 + , and CD200 + ) differentiated as in C) confirmed that GP2 is superior in enriching for PDX1 + /NKX6-1 + cells. E) Immunostainings on sorted and reseeded CD142 + and CD200 + cell fractions with PDX1 (green) and NKX6-1 (red). Scale bars, 100 µm.
FIGURE S4; relates to FIGURE 5. Differentiation of hESCs into glucose responsive insulin expressing cells. A)
Schematic illustrating the differentiation protocol (referred to as protocol C) for generating hPSC-derived insulin producing cells. AA: Activin A, CHIR: CHIR99021, RA: Retinoic acid, F2: FGF2, TPB: ((2S,5S)-(E,E)-8-(5-(4-(Trifluoromethyl)phenyl)-2,4-pentadienoylamino)benzolactam), Nog: Noggin, For: Forskolin, Alki: Alk5 inhibitor, Nic: Nicotinamide, RPMI: RPMI-1640 DF12: DMEM/F-12, B27: B27 Supplement. B) Immunofluorescence stainings of differentiated cells at the PE stage (day 18). Scale bar, 100 µm. C) Quantification of PDX1 + /NKX6-1 + cells at day 18. D) GP2 and ITGA4 staining of PECs from day 18. E) Time course analysis of INS and GLU expression in differentiated HUES4 cells. The data are shown as mean expression ± SEM (n=3). F) Immunofluorescence stainings of late stage cultures of differentiated hESCs. Scale bars, 100 µm. G) High magnification images of the immunofluorescence staining from F). Scale bars, 50 µm H) Released human C-peptide levels were measured by a static GSIS assay in differentiated hESCs at d32. Error bars represent ± SEM. n=3), **p<0.01, ****p<0.0001.
FIGURE S5; relates to FIGURE 6. Differentiation of GP2 sorted hESCs into CPEP + cells. A)
Immunofluorescence stainings of the GP2 Low fraction from differentiated HUES4 cells sorted with GP2 on day 18. The cells were reseeded and further differentiated until the end stage using the protocol depicted in Figure S4A . Scale bars, 100 µm B) Time course analysis of PDX1, NKX6-1, and NEUROG3 expression in differentiated MShef-7 cells. Error bars represent mean expression ± SEM. C) Immunofluorescence stainings of the GP2 Low fraction from differentiated MShef-7 cells sorted with GP2 on day 18. The cells were reseeded and further differentiated until the end stage using the protocol depicted in Figure S4A . Scale bar, 100 µm. D) High magnification images of immunostainings on GP2 High fraction from differentiated MShef-7 cells sorted with GP2 on day 18. The cells were reseeded and further differentiated as indicated above. Scale bars, 100 µm.
FIGURE S6
; relates to FIGURE 7. Effect of CDKN1A and CDKN2A knockdown on proliferation of late PECs. A) Time course analysis of PDX1, NKX6-1, GP2, MKI67, CDKN1A, and CDKN2A expression in differentiated hESCs. B) Insets showing NKX6-1 and GP2 expression from day 0 -day 14. The data are shown as mean expression ± SEM (n=6), * p£ 0.05, ** p£ 0.01, *** p£ 0.001, and **** p£ 0.0001. C) Schematic displaying the cell cycle and the various CDK-cyclin complexes that regulate cell cycle progression. As depicted the cell cycle regulators CDKN1A (P21) or CDKN2A (P16) regulate cell cycle by governing the activity of these complexes. D) Enrichment of the cell cycle regulators CDKN1A and CDKN2A in the PEC cells at day 17 differentiated according to protocol A depicted in Figure 1 . E,F) qPCR analysis confirmed significant knockdown of CDKN1A and CDKN2A 24h after transfection of late (d17) PECs. Error bars represent ± SEM, n=2-3, ** p£ 0.01, **** p£ 0.0001. G-H) PECs from day 17 were transfected with CDKN1a siRNA and harvested 72h later, stained with EDU and analyzed by flow cytometry. I) Relative fraction of cells (CDKN1A/Ctr siRNA) in the G0/G1, S, and G2/M phases. J,K) qPCR analysis of MKI67 expression 24h (J) and 72h (K) after transfection in late PECs. Error bars represent ± SEM, n=2-3. L) Immunofluorescence analysis 72h after knockdown of CDKN1A or CDKN2A on late PECs (d20). No significant increase of MKI67 + cells was detected compared to scrambled control. Expression of PE markers PDX1 and NKX6-1 was also unaffected. Scale bars, 100µm.
FIGURE S7; relates to FIGURE 7. Effect of CDKN1A and CDKN2A knockdown on proliferation of early PECs.
A-C) Knockdown efficiency of CDKN1A and CDKN2A in differentiated hESCs harvested 24h after transfection of early (d11) PECs was determined by qPCR and western blot. Error bars represent ± SEM, n=6, **** p£ 0.0001. D) Immunofluorescence analysis of the PE markers PDX1 and NKX6-1 72h after knockdown of CDKN1A or CDKN2A on early PECs (d14). Scale bars, 100µm. E) Quantification of PDX1 + /NKX6-1 + cells at day 14 (n=3), * p£ 0.05, ** p£ 0.01. F) Knockdown of CDKN1A or CDKN2A resulted in a significant increase in the number of cells (estimated by DAPI staining) (n=3), **** p£ 0.0001. G-I) Differentiated early PECs from day 11 were transfected with CDKN1A or CDKN2A siRNA and harvested 72h later, stained with EDU and subsequently with GP2. GP2 + cells were sorted and analyzed by flow cytometry. J-K) Relative fraction of cells (CDKN1A/Ctr siRNA and CDKN2A/Ctr siRNA) in the G0/G1, S, and G2/M phases of the cell cycle. 6, 7, S1, S2, S6, S7 .
Gene Forward primer Reverse primer
CDKN1A CTGGCATAGAAGAGGCTGGT GCATGGGTTCTGACGGACA CDKN2A CCGAATAGTTACGGTCGGAGG CACCAGCGTGTCCAGGAAG GP2 GCACTCCCTGGTGTAATCTGA CTGAGGCTGCAAACTGTGGA FOLR1 TGTCCCCTGGAATAAGGCAAG CTTGTCTGAGCCTCCCCTAC ITGA4 ACACGCTGTTCGGCTACTCG CACAAGGTTCTCCATTAGGGCT INS AACCAACACCTGTGCGGCTC AAGGGCTTTATTCCATCTCTCTCG GLU GCATTTACTTTGTGGCTGGA CGCTTGTCCTCGTTCATCT MKI67 TACAGGCCACGCAAACTCTC CATGTGCTTGTCAACTGCGG ZNF80 CTGTGACCTGCAGCTCATCCT TAAGTTCTCTGACGTTGACTGATGTG GDF3 CCTGGTTCAGGAGCCTCATG TGAAGTGAACAGCACCTTGTGG PDX1 UTR GTTTTCGTGAGCGCCCATT CTAAGAGGCTAGGCCCAGGTA
Supplemental Experimental Procedures
Human ES cell culture and differentiation Undifferentiated HUES4, obtained from D.A. Melton, Howard Hughes Medical Institute (Harvard University, Cambridge, MA) were maintained on irradiated mouse embryonic fibroblasts (MEFs) (derived by Lund Transgenic Core Facility, Lund University and the Transgenic Mice Core Facility, University of Copenhagen) in medium containing KO-DMEM, 10% knockout serum replacement (Ko-SR), 1% non-essential amino acids (NEAA), 1% Glutamax, and beta-Mercaptoethanol (Life Technologies) and 10 ng/ml bFGF (Peprotech). Cells were passaged with Accutase (Life Technologies) and re-plated at a split-ratio between 1:3 and 1:4. For feeder free culture, HUES4 and the PDXeG clone 170-3 were adapted and maintained in DEF™-CS (Takara) and passaged with TrypLE E (Life Technologies). Undifferentiated MShef-7 cells obtained from the Centre for Stem Cell Biology, University of Sheffield, were maintained on laminin-521 (LN521, Biolamina) in NutriStem hESC XF medium (Biological Industries). Cells were passaged with dissociation buffer (0.5 mM EDTA). Karyotyping was performed by standard G-banding, and for each analysis 20-25 metaphases were evaluated (Institute for Clinical Genetics at the Universities of Lund, Sweden and Cell Guidance Systems, Cambridge, UK).
Differentiation Protocol A and B
hESCs cultured on MEFs were grown until 90% confluency and differentiated into definitive endoderm (DE) by using a modified version of the D'Amour protocol (D'Amour et al., 2005) . The first day of differentiation, hESCs were cultured in the presence of 100ng/ml human Activin A (Peprotech) and 25ng/ml Wnt3a (R&D systems) in RPMI medium (Life Technologies). The four following days 100ng/ml human Activin A was added together with 1x B27-insulin in RPMI medium (Life Technologies). To generate PECs, DE cells were first treated with 2µM retinoic acid (RA, Sigma Aldrich) in DMEM/F12 medium containing 1x B27+insulin (Life Technologies) for 3 days and then finally treated with 64 ng/ml FGF2 in combination with 100 ng/ml Noggin (Peprotech) for the remaining 9 days. To generate PFG cells, DE cells were treated with 64 ng/ml FGF2 in DMEM/F12 medium containing 1x B27+insulin (Life Technologies) for 12 days.
Differentiation Protocol C
Feeder-free HUES4 and MShef-7 cells were differentiated in RPMI medium containing 100ng/ml Activin A (Peprotech) and 3µM CHIR99021 (SMS-Gruppen) the first day, and then with 100ng/ml human Activin A together with B27-Insulin for the remaining 4 days. At day 5 and the following 3 days, 2µM retinoic acid was added in DMEM/F12 medium containing 1x B27+insulin. At day eight, cells were washed, and human FGF2 was added (64 ng/ml) on occasions together with human Noggin (50ng/ml, Peprotech) in a DMEM/F12 medium supplemented with 1x B27+insulin. Medium was changed on a daily basis throughout the protocol. To promote differentiation to insulin producing cells, the cells at day 11 were treated with TPB (0,5µM, Millipore) and Noggin (100ng/ml) for 3 days and for the remaining days (up to day 32), cells were treated with Forskolin (10µM, Sigma Aldrich), Alk5 inhibitor (4.5µM, Santa Cruz), Nicotinamide (10mM, Sigma Aldrich), Noggin (100ng/ml) in DMEM/F-12 medium containing B27 Supplement (1x). The medium was replaced every second day from day 17 and onwards.
Modified Rezania protocol
The PDXeG clone 170-3 adapted to feeder-free conditions was differentiated into pancreatic endoderm following Rezania et al 2013 (Rezania et al., 2013) with slight modifications. Definitive endoderm was induced according to Funa et al 2015 (Funa et al., 2015 . The cells were then cultured for 2 days with 50 ng/ml FGF7 (Peprotech) in DMEM/F12 containing 1x B27+insulin, 2g/l sodium bicarbonate (Sigma) and 0.25 mM vitamin C (Sigma). The cells were then incubated with 2 ng/ml FGF7, 0,25µM SANT1 (Sigma), 2 µM retinoic acid (RA, Sigma Aldrich) and 100 ng/ml Noggin in DMEM high glucose (Life Technologies) supplemented with 1x B27+insulin, 2g/l sodium bicarbonate and 0.25 mM vitamin C for 4 days. Finally, the cells were incubated with 100 ng/ml Noggin and 500 nM TPB in DMEM high glucose (Life Technologies) supplemented with 1x B27+insulin, 2g/l sodium bicarbonate and 0.25 mM vitamin C for 3-5 days.
Generation of a hESC-derived PDX1-eGFP (PDXeG) reporter cell line
The PDX1-targeting vector was constructed by inserting an eGFP-pSV40-Neo R reporter cassette upstream of the PDX1 start codon (ATG), resulting in an GFP-tagged PDX1 allele. The GFP cassette was flanked by a 12.5kb 5'homologous arm and by a 3,5kb 3'homologous arm. The bacterial artificial chromosome (BAC) containing the human PDX1 locus (CTD-2270K21) purchased from Life Technologies was verified by restriction enzyme digestion and sequencing. The final targeting construct was verified by PCR, restriction analysis and sequencing. The cloning of the GFP-cassette, targeting and drug selection was performed as previously published (Fischer et al., 2010) . After approximately 2 weeks emerging clones were picked, expanded and analyzed by PCR. The Neomycin cassette was deleted by using a CRE expression vector (NLS-CRE-IRES-Puro) that was transiently co-transfected with a DsRED or GFP plasmid into selected targeted cloned. 24 hours post electroporation, GFP/DsRED positive single cells were FACS sorted and plated into 96well plates. Clones were expanded and characterized for Neo excision by PCR.
